We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

35 hedge funds and large institutions have $385K invested in Statera Biopharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 35 → 35 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

57% less capital invested

Capital invested by funds: $897K → $385K (-$512K)

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
8
Closed
2
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$3K

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$21.6K
2
UBS Group
UBS Group
Switzerland
+$18.8K
3
TSS
Two Sigma Securities
New York
+$18.4K
4
Osaic Holdings
Osaic Holdings
Arizona
+$3.15K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.5K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$58.8K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$28.6K
3
Jane Street
Jane Street
New York
-$10K
4
BPA
Beacon Pointe Advisors
California
-$5K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$2.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$176K -$58.8K -279,289 -17%
Vanguard Group
2
Vanguard Group
Pennsylvania
$49K -$2.2K -10,433 -3%
Northern Trust
3
Northern Trust
Illinois
$22K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$16K – – –
BlackRock
5
BlackRock
New York
$14K -$725 -3,444 -3%
RJFSA
6
Raymond James Financial Services Advisors
Florida
$13K -$2.11K -10,000 -9%
TSS
7
Two Sigma Securities
New York
$13K +$18.4K +87,150 +759%
UBS Group
8
UBS Group
Switzerland
$13K +$18.8K +89,346 +1,045%
VF
9
Virtu Financial
New York
$13K +$21.6K +102,385 New
Cambridge Investment Research Advisors
10
Cambridge Investment Research Advisors
Iowa
$9K – – –
State Street
11
State Street
Massachusetts
$9K – – –
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$8K – – –
Two Sigma Investments
13
Two Sigma Investments
New York
$5K -$801 -3,804 -9%
DY
14
Dowling & Yahnke
California
$4K – – –
TRCT
15
Tower Research Capital (TRC)
New York
$4K +$1.5K +7,125 +30%
Millennium Management
16
Millennium Management
New York
$3K +$1.4K +6,657 +36%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$2K -$28.6K -135,620 -89%
BBWA
18
Bell & Brown Wealth Advisors
California
$2K – – –
IA
19
IFP Advisors
Florida
$2K – – –
SCP
20
Sandhill Capital Partners
New York
$2K – – –
UCMOK
21
United Capital Management of KS
Kansas
$2K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$2K +$3.15K +14,980 +2,651%
FP
23
Financial Perspectives
Minnesota
$1.16K – – –
Carson Wealth (CWM LLC)
24
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
TAM
25
Tucker Asset Management
Colorado
$140 – – –
1
2

STAB Hedge Fund Activity: Q3 2022 in Review

35 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2022, worth a combined $385K — down 57% from $897K a quarter earlier.

Fund positioning in STAB was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 8 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $21.6K. The largest seller was Renaissance Technologies, cutting an estimated $58.8K.

  • 35 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $385K of Statera Biopharma, Inc. Common Stock stock for Q3 2022, down 57% quarter-over-quarter.
  • 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of 0 holders.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2022 was Virtu Financial, an estimated $21.6K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $58.8K sold.

Based on aggregated 13F filings for Q3 2022.